Dr. Anil Patel is the managing partner of the firm’s Houston office. He focuses
his practice on intellectual property litigation in the pharmaceutical and chemical
industries. Anil has served as lead counsel in numerous Hatch-Waxman litigation
cases. He has experience in all phases of patent litigation, including Markman
hearings, Daubert motions, direct and cross-examination of fact and expert
witnesses, fact and expert discovery and depositions, motion practice, and pre-trial
and post-trial briefing.
Anil’s scientific background along with his breadth of experience in legal
issues relevant to the pharmaceutical industry allows him to provide his clients
with sophisticated advice leading to a competitive advantage.
Anil also focuses a significant portion of his practice on advising clients on patent
licensing agreements and settlement agreements, including specific experience in
negotiating settlements of Hatch-Waxman litigations. Relatedly, he frequently
advises clients on FDA regulatory matters, with specific focus on matters relating
to regulatory exclusivities.
Additionally, Anil’s practice involves advising clients on IP due diligence
matters relating to potential acquisitions of target products and companies. In this
context, his experience includes advising clients not only on the IP related
matters, but providing an overall assessment on the impact of IP, regulatory and
other legal issues on the business potential of the target acquisition.
Anil’s experience includes counseling clients on non-infringement and
invalidity opinions, drafting Paragraph IV notice letters and detailed statements;
advising clients on products for portfolio selection, including evaluation of
potential launch dates, as well as legal and regulatory hurdles.
